Metabolic comorbidity in case of cerebrovascular pathology

Мұқаба

Дәйексөз келтіру

Толық мәтін

Ашық рұқсат Ашық рұқсат
Рұқсат жабық Рұқсат берілді
Рұқсат жабық Рұқсат ақылы немесе тек жазылушылар үшін

Аннотация

Problem of cerebral vascular pathology has serious medical and socio-economic consequences for the nation. The fastest growing risk factors for stroke are metabolic disorders – obesity and diabetes mellitus, which not only increase the probability of developing acute cerebrovascular accidents, but also negatively affect the course and prognosis of cerebrovascular diseases (CVD). Article discusses the mechanisms of CVD development in conditions of metabolic disorders and also approaches to the treatment of comorbid patients.

Толық мәтін

Рұқсат жабық

Авторлар туралы

Ksenia Antonova

Scientific Center of Neurology

Хат алмасуға жауапты Автор.
Email: kseniya.antonova@mail.ru
ORCID iD: 0000-0003-2373-2231
SPIN-код: 7737-4712
Scopus Author ID: 7004672742
ResearcherId: J-9971-2016

MD, Dr. Sci. (Medicine), endocrinologist, leading researcher at the 1st Neurological Department of Scientific Center of Neurology

Ресей, 125367, Moscow, 80 Volokolamskoe Highway

Olga Lagoda

Scientific Center of Neurology

Email: olga.lagoda@gmail.com
ORCID iD: 0000-0001-7562-4991
SPIN-код: 1789-4735
Scopus Author ID: 6507370001
ResearcherId: C-5395-2012

MD, PhD (Medicine), neurologist, senior researcher at the 1st Neurological Department

Ресей, 125367, Moscow, 80 Volokolamskoe Highway

Tatyana Shishkina

Scientific Center of Neurology

Email: shishkina-ts@list.ru
ORCID iD: 0009-0001-1934-9902

resident

Ресей, 125367, Moscow, 80 Volokolamskoe Highway

Marine Tanashyan

Scientific Center of Neurology

Email: mtanashyan@neurology.ru
ORCID iD: 0000-0002-5883-8119
Scopus Author ID: 6506228066
ResearcherId: F-8483-2014

MD, Dr. Sci. (Medicine), professor, corresponding member of RAS, deputy director for scientific work, head of the 1st Neurological Department of Scientific Center of Neurology

Ресей, 125367, Moscow, 80 Volokolamskoe Highway

Әдебиет тізімі

  1. Feigin V.L., Norrving B., Mensah G.A. Global burden of stroke. Circ Res. 2017; 120(3): 439–48. https://doi.org/10.1161/circresaha.116.308413. PMID: 28154096.
  2. Статистический сборник «Здравоохранение в России 2023». Доступ: https://rosstat.gov.ru/storage/mediabank/Zdravoohran-2023.pdf (дата обращения – 16.05.2024). [Statistical collection “Healthcare in Russia 2023”. URL: https://rosstat.gov.ru/storage/mediabank/Zdravoohran-2023.pdf (date of access – 16.05.2024) (In Russ.)].
  3. Feigin V., Brainin M., Norrving B. et al. World Stroke Organization (WSO): Global stroke fact sheet 2022. Int J Stroke. 2022; 17(1): 18–29. https://doi.org/10.1177/17474930211065917. PMID: 34986727.
  4. Sun H., Saeedi P., Karuranga S. et al. IDF Diabetes Atlas: Global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045. Diabetes Res Clin Pract. 2022; 183: 109119. https://doi.org/10.1016/j.diabres.2021.109119. PMID: 34879977.
  5. Shiozawa M., Kaneko H., Itoh H. et al. Association of body mass index with ischemic and hemorrhagic stroke. Nutrients. 2021; 13(7): 2343. https://doi.org/10.3390/nu13072343. PMID: 34371853. PMCID: PMC8308685.
  6. Hayden M.R. Overview and new insights into the metabolic syndrome: Risk factors and emerging variables in the development of type 2 diabetes and cerebrocardiovascular disease. Medicina. 2023; 59(3): 561. https://doi.org/10.3390/medicina59030561. PMID: 36984562. PMCID: PMC10059871.
  7. Grundy S.M., Brewer H.B.Jr., Cleeman J.I. et al. Definition of metabolic syndrome: Report of the National Heart, Lung, and Blood Institute / American Heart Association conference on scientific issues related to definition. Circulation. 2004; 109(3): 433–38. https://doi.org/10.1161/01.cir.0000111245.75752.c6. PMID: 14744958.
  8. World Population Prospects 2022. Summary of results. United Nations Department of Economic and Social Affairs. URL: https://www.un.org/development/desa/pd/sites/www.un.org.development.desa.pd/files/wpp2022_summary_of_results.pdf (date of access – 16.05.2024).
  9. Mosenzon O., Cheng A.Y., Rabinstein A.A., Sacco S. Diabetes and stroke: What are the connections? J Stroke. 2023; 25(1): 26–38. https://doi.org/10.5853/jos.2022.02306. PMID: 36592968. PMCID: PMC9911852.
  10. Lau L.H., Lew J., Borschmann K. et al. Prevalence of diabetes and its effects on stroke outcomes: A meta-analysis and literature review. J Diabetes Investig. 2019; 10(3): 780–92. https://doi.org/10.1111/jdi.12932. PMID: 30220102. PMCID: PMC6497593.
  11. Echouffo-Tcheugui J.B., Xu H., Matsouaka R.A. et al. Diabetes and long-term outcomes of ischaemic stroke: Findings from get with the guidelines-stroke. Eur Heart J. 2018; 39(25): 2376–86. https://doi.org/10.1093/eurheartj/ehy036. PMID: 29438515. PMCID: PMC6031049.
  12. Zhang L., Li X., Wolfe C.D.A. et al. Diabetes as an independent risk factor for stroke recurrence in ischemic stroke patients: An updated meta-analysis. Neuroepidemiology. 2021; 55(6): 427–35. https://doi.org/10.1159/000519327. PMID: 34673640.
  13. Калашников В.Ю., Викулова О.К., Железнякова А.В. с соавт. Эпидемиология сердечно-сосудистых заболеваний у больных сахарным диабетом по данным Федерального регистра Российской Федерации (2013–2016 гг.). Сахарный диабет. 2019; 22(2): 105–114. [Kalashnikov V.Yu., Vikulova O.K., Zheleznyakova A.V. et al. Epidemiology of cardiovascular diseases among patients with diabetes mellitus according to the Federal Diabetes register of the Russian Federation (2013–2016). Sakharnyy diabet = Diabetes Mellitus. 2019; 22(2): 105–114 (In Russ.)]. https://doi.org/10.14341/DM10167. EDN: GVNITG.
  14. Танашян M.M., Антонова К.В., Лагода О.В. с соавт. Острые нарушения мозгового кровообращения и сахарный диабет 2 типа. Анналы клинической и экспериментальной неврологии. 2014; 8(3): 4–8. [Tanashyan M.M., Antonova K.V., Lagoda O.V. et al. Acute disorders of cerebral circulation and type 2 diabetes mellitus. Annaly klinicheskoy i eksperimental’noy nevrologii = Annals of Clinical and Experimental Neurology. 2014; 8(3): 4–8 (In Russ.)]. EDN: SQUYBZ.
  15. International Diabetes Federation Diabetes Atlas. Diabetes around the world in 2021. URL: https://diabetesatlas.org (date of access – 16.05.2024).
  16. Kunutsor S.K., Balasubramanian V.G., Zaccardi F. et al. Glycaemic control and macrovascular and microvascular outcomes: A systematic review and meta-analysis of trials investigating intensive glucose-lowering strategies in people with type 2 diabetes. Diabetes Obes Metab. 2024; 26(6): 2069–81. https://doi.org/10.1111/dom.15511. PMID: 38409644.
  17. Krinock M.J., Singhal N.S. Diabetes, stroke, and neuroresilience: Looking beyond hyperglycemia. Ann N Y Acad Sci. 2021; 1495(1): 78–98. https://doi.org/10.1111/nyas.14583. PMID: 33638222.
  18. Sharma S., Brown C.E. Microvascular basis of cognitive impairment in type 1 diabetes. Pharmacol Ther. 2022; 229: 107929. https://doi.org/10.1016/j.pharmthera.2021.107929. PMID: 34171341.
  19. Shiozawa M. Association of body mass index with ischemic and hemorrhagic stroke. Nutrients. 2021; 13(7): 2343. https://doi.org/10.3390/nu13072343. PMID: 34371853. PMCID: PMC8308685.
  20. Horn J.W., Feng T., Mørkedal B. et al. Obesity and risk for first ischemic stroke depends on metabolic syndrome: The HUNT study. Stroke. 2021; 52(11): 3555–61. https://doi.org/10.1161/strokeaha.120.033016. PMID: 34281375.
  21. Hayden M.R. Brain endothelial cells play a central role in the development of enlarged perivascular spaces in the metabolic syndrome. Medicina. 2023; 59(6): 1124. https://doi.org/10.3390/medicina59061124. PMID: 37374328. PMCID: PMC10301410.
  22. Van Dyken P., Lacoste B. Impact of metabolic syndrome on neuroinflammation and the blood-brain barrier. Front. Neurosci. 2018; 12: 930. https://doi.org/10.3389/fnins.2018.00930. PMID: 30618559. PMCID: PMC6297847.
  23. Bokura H., Yamaguchi S., Iijima K. et al. Metabolic syndrome is associated with silent ischemic brain lesions. Stroke. 2008; 39(5): 1607–9. https://doi.org/10.1161/strokeaha.107.508630. PMID: 18323475.
  24. Thijs V., Lemmens R., Schoofs C. et al. Microbleeds and the risk of recurrent stroke. Stroke. 2010; 41(9): 2005–9. https://doi.org/10.1161/strokeaha.110.588020. PMID: 20651265.
  25. Mitaki S., Takayoshi H., Nakagawa T. et al. Metabolic syndrome is associated with incidence of deep cerebral microbleeds. PLoS One. 2018; 13(3): e0194182. https://doi.org/10.1371/journal.pone.0194182. PMID: 29518124. PMCID: PMC5843289.
  26. Yaffe K. Metabolic syndrome and cognitive disorders: Is the sum greater than its parts? Alzheimer Dis Assoc Disord. 2007; 21(2): 167–71. https://doi.org/10.1097/wad.0b013e318065bfd6. PMID: 17545744.
  27. Alfaro F.J., Gavrieli A., Saade-Lemus P. et al. White matter microstructure and cognitive decline in metabolic syndrome: A review of diffusion tensor imaging. Metabolism. 2018; 78: 52–68. https://doi.org/10.1016/j.metabol.2017.08.009. PMID: 28920863. PMCID: PMC5732847.
  28. Rink C., Khanna S. Significance of brain tissue oxygenation and the arachidonic acid cascade in stroke. Antioxid Redox Signal. 2011; 14(10): 1889–903. https://doi.org/10.1089/ars.2010.3474. PMID: 20673202. PMCID: PMC3078506.
  29. Hayden M.R. Endothelial activation and dysfunction in metabolic syndrome, type 2 diabetes and coronavirus disease 2019. J Int Med Res. 2020; 48(7): 300060520939746. https://doi.org/10.1177/0300060520939746. PMID: 32722979. PMCID: PMC7391440.
  30. Silveira Rossi J.L., Barbalho S.M., Reverete de Araujo R. et al. Metabolic syndrome and cardiovascular diseases: Going beyond traditional risk factors. Diabetes Metab Res Rev. 2022; 38(3): e3502. https://doi.org/10.1002/dmrr.3502. PMID: 34614543.
  31. Юбицкая Н.С., Антонюк М.В., Веремчук Л.В., Ходосова К.К. Роль фактора некроза опухоли в развитии метаболического синдрома. Терапевтический архив. 2009; 81(11): 59–63. [Yubitskaia N.S., Antonyuk M.V., Veremchuk L.V., Khodosova K.K. Role of tumor necrosis factor in the development of metabolic syndrome. Terapevticheskiy arkhiv = Therapeutic Archive. 2009; 81(11): 59–63 (In Russ.)]. EDN: KZWZDT.
  32. Elks C.M., Francis J. Central adiposity, systemic inflammation, and the metabolic syndrome. Curr Hypertens Rep. 2010; 12(2): 99–104. https://doi.org/10.1007/s11906-010-0096-4. PMID: 20424938.
  33. Donath M.Y., Shoelson S.E. Type 2 diabetes as an inflammatory disease. Nat Rev Immunol. 2011; 11(2): 98–107. https://doi.org/10.1038/nri2925. PMID: 21233852.
  34. Танашян М.М., Антонова К.В., Лагода О.В. с соавт. Ожирение и протромбогенное состояние крови у пациентов с цереброваскулярными заболеваниями. Тромбоз, гемостаз и реология. 2023; (3): 53–62. [Tanashyan M.M., Antonova K.V., Lagoda O.V. et al. Obesity and prothrombogenic blood condition in patients with cerebrovascular diseases. Tromboz, gemostaz i reologiya = Thrombosis, Hemostasis and Rheology. 2023; (3): 53–62 (In Russ.)]. https://doi.org/10.25555/THR.2023.3.1069. EDN: JYCOMF.
  35. Танашян М.М., Антонова К.В., Раскуражев А.А. с соавт. Цереброваскулярные заболевания и глюколипотоксичность. Анналы клинической и экспериментальной неврологии. 2020; 14(1): 17–24. [Tanashyan M.M., Antonova K.V., Raskurazhev A.A. et al. Cerebrovascular disorders and glucolipotoxicity. Annaly klinicheskoy i eksperimental’noy nevrologii = Annals of Clinical and Experimental Neurology. 2020; 14(1): 17–24 (In Russ.)]. https://doi.org/0.25692/ACEN.2020.1.2. EDN: BBQBEC.
  36. Wong Zhang D.E., Tran V., Vinh A. et al. Pathophysiological links between obesity and dementia. Neuromolecular Med. 2023; 25(4): 451–56. https://doi.org/10.1007/s12017-023-08746-1. PMID: 37086380. PMCID: PMC10721659.
  37. Morley J.E. Diabetes: The diabetic brain. Nat Rev Endocrinol. 2017; 13(10): 570–71. https://doi.org/10.1038/nrendo.2017.111. PMID: 28895951.
  38. Neto A.M., Parisi M.C.R., Tambascia M.A. et al. Relationship of thyroid hormone levels and cardiovascular events in patients with type 2 diabetes. Endocrine. 2014; 45(1): 84–91.
  39. https//doi.org/10.1007/s12020-013-9938-6. PMID: 23546612.
  40. Yang M.H., Yang F.Y., Lee D.D. Thyroid disease as a risk factor for cerebrovascular disease. J Stroke Cerebrovasc Dis. 2015; 24(5): 912–20. https://doi.org/10.1016/j.jstrokecerebrovasdis.2014.11.032. PMID: 25804562.
  41. Ткачук А.В., Михина М.С., Ибрагимова Л.И. с соавт. Сахарный диабет и аутоиммунные заболевания щитовидной железы. Вестник РАМН. 2020; 75(6): 647–652. [Tkachuk A.V., Mikhina M.S., Ibragimova L.I. et al. Diabetes mellitus and autoimmune diseases of the thyroid gland. Vestnik RAMN = Bulletin of the Russian Academy of Medical Sciences. 2020; 75(6): 647–652 (In Russ.)]. https://doi.org/10.15690/vramn1182. EDN: QPOLCB.
  42. Longo S., Rizza S., Federici M. Microbiota-gut-brain axis: Relationships among the vagus nerve, gut microbiota, obesity, and diabetes. Acta Diabetol. 2023; 60(8): 1007–17. https://doi.org/10.1007/s00592-023-02088-x. PMID: 37058160. PMCID: PMC10289935.
  43. Loffredo L., Ettorre E., Zicari A.M. et al. Oxidative stress and gutderived lipopolysaccharides in neurodegenerative disease: Role of NOX2. Oxid Med Cell Longev. 2020; 2020: 8630275. https://doi.org/10.1155/2020/8630275. PMID: 32089785. PMCID: PMC7016401.
  44. Nedosugova L.V., Balabolkin M.I., Lisina M.O. et al. Interrelation between compensation of carbohydrate metabolism and severity of manifestations of oxidative stress in type II diabetes mellitus. Bulletin of Experimental Biology and Medicine. 2003; 136(2): 132–34. https://doi.org/10.1023/A:1026302520288. EDN: LHSWGP.
  45. Стаховская Л.В., Мхитарян Э.А., Ткачева О.Н. с соавт. Эффективность и безопасность Мексидола у пациентов разных возрастных групп в остром и раннем восстановительном периодах полушарного ишемического инсульта (результаты субанализа рандомизированного двойного слепого мультицентрового плацебоконтролируемого в параллельных группах исследования ЭПИКА). Журнал неврологии и психиатрии им. С.С. Корсакова. 2020; 120(8–2): 49–57. [Stakhovskaya L.V., Mkhitaryan E.A., Tkacheva O.N. et al. Efficacy and safety of mexidol across age groups in the acute and early recovery stages of hemispheric ischemic stroke (results of additional sub-analysis of a randomized double blind multicenter placebo-controlled study, in parallel groups trial EPICA). Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova = S.S. Korsakov Journal of Neurology and Psychiatry. 2020; 120(8–2): 49–57 (In Russ.)]. https://doi.org/10.17116/jnevro202012008249. EDN: JKKCFP.
  46. Щепанкевич Л.А., Николаев Ю.А., Долгова Н.А., Чипова Д.Т. Оптимизация липидснижающей терапии у пациентов с ишемическим инсультом и сахарным диабетом 2-го типа. Журнал неврологии и психиатрии им. С.С. Корсакова. 2016; 116(2): 42–45. [Shchepankevich L.A., Nikolaev Yu.A., Dolgova N.A., Chipova D.T. Optimization of hypolipidemic therapy in patients with ischemic stroke and diabetes mellitus. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova = S.S. Korsakov Journal of Neurology and Psychiatry. 2016; 116(2): 42–45 (In Russ.)]. https://doi.org/10.17116/jnevro20161162142-45. EDN: VNZZNR.
  47. Пугачева Е.Л. Эффективность препарата Мексидол у пациентов с неврологическими осложнениями сахарного диабета 2-го типа. Журнал неврологии и психиатрии им. С.С. Корсакова. 2022; 122(5): 84–89. [Pugacheva E.L. Efficacy of Mexidol inpatients with type 2 diabetes mellitus with neurological complications. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova = S.S. Korsakov Journal of Neurology and Psychiatry. 2022; 122(5): 84–89 (In Russ.)]. https://doi.org/10.17116/jnevro202212205184. EDN: UQRBPB.
  48. Баженова Л.Н., Володина Н.Н., Фролова Н.П. Влияние препарата «Мексидол» на эндотелиальную дисфункцию у больных с хронической сердечной недостаточностью. Бюллетень экспериментальной биологии и медицины. 2006; (S1): 96–100. [Bazhenova L.N., Volodina N.N., Frolova N.P. The effect of the drug Mexidol on endothelial dysfunction in patients with chronic heart failure. Byulleten’ eksperimental’noy biologii i meditsiny = Bulletin of Experimental Biology and Medicine. 2006; (S1): 96–100 (In Russ.)].
  49. Толкачева В.В., Казахмедов Э.Р., Кобалава Ж.Д. с соавт. Влияние Мексидола на качество жизни и функциональный статус пациентов с хронической ишемией головного мозга и хронической сердечной недостаточностью с низкой фракцией выброса. Кардиология и сердечно-сосудистая хирургия. 2021; 14(1): 80–89. [Tolkacheva V.V., Kazakhmedov E.R., Kobalava Zh.D. et al. Effect of Mexidol on the quality of life and functional status of patients with chronic cerebral ischemia and chronic heart failure with reduced left ventricular ejection fraction. Kardiologiya i serdechno-sosudistaya khirurgiya = Cardiology and Cardiovascular Surgery. 2021; 14(1): 80–89 (In Russ.)]. https://doi.org/10.17116/kardio20211401180. EDN: CEYVUA.
  50. Сагынбаева Г.А., Калиев Р.Р. Эффективность n-ацетилцистеина и мексидола в профилактике контраст-индуцированной нефропатии у больных коронарной болезнью сердца. Наука, новые технологии и инновации Кыргызстана. 2020; (8): 26–33. [Sagynbayeva G.A., Kaliev R.R. Efficacy of n-acetylcysteine and mexidol in the prevention of contrast-induced nephropathy in patients with coronary heart disease. Nauka, novyye tekhnologii i innovatsii Kyrgyzstana = Science, New Technologies and Innovations of Kyrgyzstan. 2020; (8): 26–33 (In Russ.)]. https://doi.org/10.26104/NNTIK.2019.45.557. EDN: GNDDUP.
  51. Карманова Е.Е., Черников А.В., Усачева А.М., Брусков В.И. Антиоксидантные и генопротекторные свойства этилметилгидроксипиридина сукцината (мексидола) при рентгеновском облучении. Химико-фармацевтический журнал. 2020; 54(7): 10–14. [Karmanova E.E., Chernikov A.V., Usacheva A.M., Bruskov V.I. Antioxidant and genoprotective properties of ethylmethylhydroxypyridine succinate (mexidol) under X-ray irradiation. Khimiko-farmatsevticheskiy zhurnal = Chemico-Pharmaceutical Journal. 2020; 54(7): 10–14 (In Russ.)]. https://doi.org/10.30906/0023-1134-2020-54-7-10-14. EDN: CPEPBY.
  52. Абдрашитова А.Т., Панова Т.Н., Эсаулова Т.А. Эффективность комбинированной терапии мексидолом и крестором в комплексной профилактике преждевременного старения. Астраханский медицинский журнал. 2011; 6(4): 29–32. [Abdrashitova A.T., Panova T.N., Esaulova T.A. The efficiency of combined therapy by mexidol and crestor in complex prophylaxis of presenilation. Astrakhanskiy meditsinskiy zhurnal = Astrakhan Medical Journal. 2011; 6(4): 29–32 (In Russ.)]. EDN: OYXXYB.
  53. Радько С.В., Дулепов А.Д. Влияние сукцинатсодержащих препаратов на физическую работоспособность и восстановление после нагрузок. Фармакокинетика и фармакодинамика. 2019; (1): 3–5. [Radko S.V., Dulepov A.D. The influence of succinate-containing drugs on physical performance and recovery after exercise. Farmacokinetika i farmacodynamika = Pharmacokinetics and Pharmacodynamics. 2019; (1): 3–5 (In Russ.)]. https://doi.org/10.24411/2587-7836-2019-10032. EDN: AXKXAL.
  54. Танашян М.М., Антонова К.В., Лагода О.В. с соавт. Приверженность лечению у пациентов с цереброваскулярными заболеваниями как мультифакториальная проблема. Неврология, нейропсихиатрия, психосоматика. 2023; 15(1): 18–27. [Tanashyan M.M., Antonova K.V., Lagoda O.V. et al. Adherence to treatment in patients with cerebrovascular disease as amultifactorial problem. Nevrologiya, neiropsikhiatriya, psikhosomatika = Neurology, Neuropsychiatry, Psychosomatics. 2023; 15(1): 18–27 (In Russ.)].
  55. Танашян М.М., Лагода О.В., Антонова К.В. Хронические цереброваскулярные заболевания на фоне метаболического синдрома: новые подходы к лечению. Журнал неврологии и психиатрии им. С.С. Корсакова. 2012; 112(11): 21–26. [Tanashyan M.M., Lagoda O.V., Antonova K.V. Chronic Cerebrovascular Diseases on the Background of Metabolic Syndrome: New Approaches to Treatment Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova = S.S. Korsakov Journal of Neurology and Psychiatry. 2012; 112(11): 21–26 (In Russ.)]. https://doi.org/10.14412/2074-2711-2023-1-18-27. EDN: RYHAHF.

Қосымша файлдар

Қосымша файлдар
Әрекет
1. JATS XML
Жүктеу
2. Fig. “Metabolic ill health” as a cluster of interrelated risks and variables associated with an increased risk of developing cerebrocardiovascular diseases and type 2 diabetes mellitus

Жүктеу (1020KB)
Метадеректер

© Bionika Media, 2024

Осы сайт cookie-файлдарды пайдаланады

Біздің сайтты пайдалануды жалғастыра отырып, сіз сайттың дұрыс жұмыс істеуін қамтамасыз ететін cookie файлдарын өңдеуге келісім бересіз.< / br>< / br>cookie файлдары туралы< / a>